Dr Reddy’s Laboratories Dips 3%: Credit Suisse Has Maintained Outperform

Dr Reddy’s Laboratories dips 3%: Credit Suisse has maintained outperform call with a target at Rs 3,055 per share.

Expect company to launch generic of NuvaRing in H2FY21. The large market size still makes it attractive for the later generic entrants. Teva & Mayne Pharma may expect approval in CY20 as well.

Share price of Premier Explosives zoomed over 17 percent intraday on December 13 after the the company received license from Government of Telangana to work on a factory at Katepally, near Hyderabad. The stock also witnessed spurt in volume by more than 11.63 times.

For more information ✆ +91- 6232578593 or visit www.moneymarketmanthan.com